Adma Biologics reported $73.54M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Adma Biologics USD 73.54M 4M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Novavax USD 342.46M 117.49M Mar/2026
Omeros USD 85.5M 2.28M Jun/2025
Takeda JPY 2.43T 180.65B Mar/2026